European Patent Office limits Harvard's "oncomouse" patent

Munich, 7 November 2001 — The EPO opposition division dealing with Harvard University's "oncomouse" patent has decided to maintain it in amended form. After a two-day hearing, the division ruled that the patent must be limited to transgenic rodents containing an additional cancer gene. This decision can be appealed by the patentee or any of the opponents.